Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7798867 | 0.85 | FDPS (0.52) | FDPSHDAC1HDAC6LTA4HDNMT3B | |
| SCHEMBL6948592 | 0.84 | FDPS (0.55) | FDPSHDAC1HDAC6LTA4HDNMT3B | |
| SCHEMBL20305125 | 0.84 | FDPS (0.51) | FDPSHDAC1HDAC6LTA4HDNMT3B | |
| SCHEMBL9936014 | 0.81 | FDPS (0.62) | FDPSHDAC1HDAC6LTA4HDNMT3B | |
| SCHEMBL1692456 | 0.79 | FDPS (0.56) | FDPSHDAC1HDAC6LTA4HDNMT3B | |
| SCHEMBL11200763 | 0.78 | FDPS (0.54) | FDPSHDAC1HDAC6LTA4HDNMT3B | |
| SCHEMBL10857669 | 0.78 | FDPS (0.54) | FDPSHDAC1HDAC6LTA4HDNMT3B | |
| SCHEMBL28817988 | 0.78 | FDPS (0.54) | FDPSHDAC1HDAC6LTA4HDNMT3B | |
| SCHEMBL28126755 | 0.77 | FDPS (0.55) | FDPSHDAC1HDAC6LTA4HDNMT3B | |
| SCHEMBL27932506 | 0.76 | FDPS (0.53) | FDPSHDAC1HDAC6LTA4HDNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214198-A1 | Allele-targeted RNA interference | UNIVERSITY OF MASSACHUSETTS | 2004-10-28 | — | — | US | claimed |
| WO-2004046324-A2 | ALLELE-TARGETED RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2004-06-03 | — | — | WO | claimed |
| US-9878050-B2 | Delivery of agents using interfering nanoparticles | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170182177-A1 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SANFORD-BURNHAM MEDICAL RES INST (US) | 2017-06-29 | — | — | US | disclosed |
| US-9526693-B2 | Delivery of agents using interfering nanoparticles | Sanford-Burnham Medical Research Inslilute (US) | 2016-12-27 | — | — | US | disclosed |
| US-20110263514-A1 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011116152-A2 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SANFORD -BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-22 | — | — | WO | disclosed |
| US-7951784-B2 | modified small interfering RNAs (siRNAs) that are stable in vivo and retain the ability to form an A-form helix when in association with a target RNA; gene expression inhibition; for treating amyotrophic lateral sclerosis associated with the activity of a protein specified by a target mRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1986699-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | University of Massachusetts (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1986609-A2 | RNA SILENCING AGENTS FOR USE IN THERAPY AND NANOTRANSPORTERS FOR EFFICIENT DELIVERY OF SAME | University of Massachusetts (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080125386-A1 | RNA interference agents for therapeutic use | UNIVERSTIY OF MASSACHUSETTS (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2007092182-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007089607-A2 | RNA SILENCING AGENTS FOR USE IN THERAPY AND NANOTRANSPORTERS FOR EFFICIENT DELIVERY OF SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20040214198-A1 | Allele-targeted RNA interference | UNIVERSITY OF MASSACHUSETTS | 2004-10-28 | — | — | US | disclosed |
| WO-2004046324-A2 | ALLELE-TARGETED RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125386-A1 | RNA interference agents for therapeutic use | HNRNPH1, SNRPE, RNASEH1 | FDPS 4160/4885HDAC1 661/4885HDAC6 150/4885 |
| US-20170182177-A1 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SNRPE, SNRPF, SNRPA | FDPS 3495/4885HDAC1 1042/4885HDAC6 343/4885 |
| US-20110263514-A1 | DELIVERY OF AGENTS USING INTERFERING NANOPARTICLES | SNRPE, SNRPF, SNRPA | FDPS 3495/4885HDAC1 1042/4885HDAC6 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.